Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
Salisch NC, Stephenson KE, Williams K, Cox F, van der Fits L, Heerwegh D, Truyers C, Habets MN, Kanjilal DG, Larocca RA, Abbink P, Liu J, Peter L, Fierro C, De La Barrera RA, Modjarrad K, Zahn RC, Hendriks J, Cahill CP, Leyssen M, Douoguih M, van Hoof J, Schuitemaker H, Barouch DH. Salisch NC, et al. Among authors: van der fits l. Ann Intern Med. 2021 May;174(5):585-594. doi: 10.7326/M20-5306. Epub 2021 Feb 16. Ann Intern Med. 2021. PMID: 33587687 Clinical Trial.
Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge.
Cox F, van der Fits L, Abbink P, Larocca RA, van Huizen E, Saeland E, Verhagen J, Peterson R, Tolboom J, Kaufmann B, Schuitemaker H, Barouch DH, Zahn R. Cox F, et al. Among authors: van huizen e, van der fits l. PLoS One. 2018 Aug 24;13(8):e0202820. doi: 10.1371/journal.pone.0202820. eCollection 2018. PLoS One. 2018. PMID: 30142207 Free PMC article.
Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
He X, Chandrashekar A, Zahn R, Wegmann F, Yu J, Mercado NB, McMahan K, Martinot AJ, Piedra-Mora C, Beecy S, Ducat S, Chamanza R, Huber SR, van Heerden M, van der Fits L, Borducchi EN, Lifton M, Liu J, Nampanya F, Patel S, Peter L, Tostanoski LH, Pessaint L, Van Ry A, Finneyfrock B, Velasco J, Teow E, Brown R, Cook A, Andersen H, Lewis MG, Schuitemaker H, Barouch DH. He X, et al. Among authors: van der fits l. Cell. 2021 Jun 24;184(13):3467-3473.e11. doi: 10.1016/j.cell.2021.05.040. Epub 2021 Jun 1. Cell. 2021. PMID: 34133941 Free PMC article.
Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
Saeland E, van der Fits L, Bolder R, Heemskerk-van der Meer M, Drijver J, van Polanen Y, Vaneman C, Tettero L, Serroyen J, Schuitemaker H, Callendret B, Langedijk JPM, Zahn RC. Saeland E, et al. Among authors: van der fits l. Vaccine. 2022 Feb 7;40(6):934-944. doi: 10.1016/j.vaccine.2021.12.043. Epub 2021 Dec 29. Vaccine. 2022. PMID: 34973849 Free article.
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.
van der Lubbe JEM, Rosendahl Huber SK, Vijayan A, Dekking L, van Huizen E, Vreugdenhil J, Choi Y, Baert MRM, Feddes-de Boer K, Izquierdo Gil A, van Heerden M, Dalebout TJ, Myeni SK, Kikkert M, Snijder EJ, de Waal L, Stittelaar KJ, Tolboom JTBM, Serroyen J, Muchene L, van der Fits L, Rutten L, Langedijk JPM, Barouch DH, Schuitemaker H, Zahn RC, Wegmann F. van der Lubbe JEM, et al. Among authors: van der fits l. NPJ Vaccines. 2021 Mar 19;6(1):39. doi: 10.1038/s41541-021-00301-y. NPJ Vaccines. 2021. PMID: 33741993 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33580084
Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques.
He X, Chandrashekar A, Zahn R, Wegmann F, Yu J, Mercado NB, McMahan K, Martinot AJ, Piedra-Mora C, Beecy S, Ducat S, Chamanza R, Huber SR, van der Fits L, Borducchi EN, Lifton M, Liu J, Nampanya F, Patel S, Peter L, Tostanoski LH, Pessaint L, Van Ry A, Finneyfrock B, Velasco J, Teow E, Brown R, Cook A, Andersen H, Lewis MG, Schuitemaker H, Barouch DH. He X, et al. Among authors: van der fits l. bioRxiv [Preprint]. 2021 Jan 27:2021.01.27.428380. doi: 10.1101/2021.01.27.428380. bioRxiv. 2021. PMID: 33532782 Free PMC article. Updated. Preprint.
EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L, van der Fits L, Zoutman WH, Out-Luiting JJ, Siegal G, de Esch IJ, Vermeer MH, Tensen CP. Hameetman L, et al. Among authors: van der fits l. Oncotarget. 2015 Oct 13;6(31):31868-76. doi: 10.18632/oncotarget.5573. Oncotarget. 2015. PMID: 26376612 Free PMC article.
NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L, Qin Y, Out-Luiting JJ, Vermeer KG, Whittaker S, van Es JH, Tensen CP, Vermeer MH. van der Fits L, et al. Among authors: van es jh. J Invest Dermatol. 2012 Dec;132(12):2810-7. doi: 10.1038/jid.2012.203. Epub 2012 Jun 21. J Invest Dermatol. 2012. PMID: 22718117 Free article.
49 results